Dr. Syed M. Kazmi
Claim this profileUT Southwestern/Simmons Cancer Center-Dallas
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
33 drugs studied
Area of expertise
1Colorectal Cancer
Global LeaderStage IV
Stage III
BRAF positive
2Colon Cancer
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Syed M. Kazmi is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
ATRA + Bevacizumab + Atezolizumab
for Colorectal Cancer
The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.
Recruiting1 award Phase 210 criteria
More about Syed M. Kazmi
Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Syed M. Kazmi has experience with
- Atezolizumab
- Nivolumab
- Cetuximab
- Bevacizumab
- Fluorouracil
- Leucovorin
Breakdown of trials Syed M. Kazmi has run
Colorectal Cancer
Colon Cancer
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Syed M. Kazmi specialize in?
Syed M. Kazmi focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Syed M. Kazmi currently recruiting for clinical trials?
Yes, Syed M. Kazmi is currently recruiting for 11 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Syed M. Kazmi has studied deeply?
Yes, Syed M. Kazmi has studied treatments such as Atezolizumab, Nivolumab, Cetuximab.
What is the best way to schedule an appointment with Syed M. Kazmi?
Apply for one of the trials that Syed M. Kazmi is conducting.
What is the office address of Syed M. Kazmi?
The office of Syed M. Kazmi is located at: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas 75390 United States. This is the address for their practice at the UT Southwestern/Simmons Cancer Center-Dallas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.